Relief for Acute Throat Inflammation and Discomfort

The medication is commonly used in clinical settings that involve acute or unstable symptom patterns. The product is relevant for easing symptoms related to inflammatory or irritative states. It is typically applied across conditions presenting with acute episodes, including pharyngitis, tonsillitis, stomatitis, and gingivitis. The product is commonly used to help address symptoms that interfere with daily functioning, such as sore throat and difficulty swallowing (dysphagia).

It supports the patient during difficult episodes by easing distress and contributes to improved comfort during periods of heightened symptoms. It is also applied in specific scenarios, such as managing mild sore throat from professional vocal strain or providing supportive relief for postoperative wound healing after procedures like tonsillectomy.

“The product is relevant for offering symptomatic relief, and provides support that helps ease the overall symptom burden.”

---

Quick Fact: Relief for Localized Discomfort
The product may be part of symptomatic management for inflammation-related pain and supports the repair of tissue in the mouth and throat, including minor lesions like aphthae.

Who Can and Cannot Use Лисобакт?

The official eligibility profile for the Lysozyme Chloride and Pyridoxine Hydrochloride lozenge (Лисобакт) is strictly defined by regulatory criteria regarding age, physiological state, and documented hypersensitivities.

---

Contraindicated Populations

The medicine is contraindicated and must not be used by individuals with a known hypersensitivity to either active ingredient—Lysozyme Chloride or Pyridoxine Hydrochloride (Vitamin B6). Furthermore, patients with a documented allergy to eggs or egg white are absolutely contraindicated, as lysozyme is commonly sourced from egg albumen. Hypersensitivity to any of the formulation's excipients is also an absolute contraindication.

---

Age and Physiological Restrictions

Population Group	Regulatory Status
Children under 6 years	Contraindicated/Not Recommended (Use not established)
Adults and Children geq 6 years	Allowed (Under standard labeled conditions)
Pregnancy	Not Recommended (Use with caution only if supervised)
Lactation/Breastfeeding	Not Recommended (Use with caution only if supervised)

---

Conditional Eligibility

Use is subject to caution for patients taking high doses of pyridoxine over a prolonged period due to potential neurological risks. Patients with known intolerance to the excipients, such as certain sugars, must also proceed with caution as stated in the official labeling.

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for the product’s active components, primarily focusing on Pyridoxine Hydrochloride (Vitamin B6), as specified in authoritative government regulatory sources.

---

Interaction Scope

Category	Description
Medicinal product categories with documented interactions	Anti-Parkinson agents, anti-tubercular agents, immunosuppressants, hormonal contraceptives, anti-epileptic agents.
Specific interacting medicines (if explicitly listed)	Levodopa (without a dopa decarboxylase inhibitor), isoniazid, penicillamine, oral contraceptives, phenobarbitone, cycloserine.
Mechanistic basis of interactions (only if stated in label)	Pharmacodynamic antagonism (reduction of therapeutic effect) and altered metabolism/bioavailability (leading to increased vitamin requirement or decreased drug concentration).

---

Official Interaction Statements:

• Pyridoxine is officially documented to increase the peripheral metabolisation of levodopa, which reduces the therapeutic effect of levodopa. This restriction is stated to be prevented when levodopa is combined with a dopa decarboxylase inhibitor.
• Co-administration with isoniazid, penicillamine, and oral contraceptives containing oestrogens may increase the systemic requirement for Pyridoxine, indicating altered metabolism of the vitamin component.
• Official regulatory sources report that Pyridoxine may decrease the serum concentrations of phenobarbitone.
• Cycloserine is documented to potentially antagonise the effects of pyridoxine.
• No timing-based interaction rules or mandatory separation requirements from other medicines are explicitly documented in official labeling.

---

Connection to the overall interaction profile

Official regulatory documents define the product’s interaction structure primarily through the known systemic interactions of its Pyridoxine component. These interactions establish documented instances where Pyridoxine either reduces the efficacy of other specific medicines (e.g., levodopa and phenobarbitone) or where other specific medicines (e.g., isoniazid, oral contraceptives) alter the metabolism or increase the systemic requirement for the vitamin component. The profile is strictly based on these formal, documented effects.

Lysozyme, a specific enzyme, mediates a dual mechanism localized to the oral and pharyngeal mucosa. The primary action involves the hydrolytic destruction of peptidoglycan, a crucial structural component of bacterial cell walls, leading to immediate osmotic imbalance and microbial cell death. Concurrently, Lysozyme mediates a local anti-inflammatory effect through the modulation and interference of pro-inflammatory signaling cascades (such as JNK signaling) in local immune cells, which results in the restricted release of pro-inflammatory mediators.

The secondary mechanism is driven by Pyridoxine (Vitamin B6), which functions as an epitheliotropic agent. It acts as a precursor to a coenzyme, facilitating the metabolic pathways necessary for protein synthesis and cellular turnover required by the oral mucosal epithelium. This mechanism contributes to cellular renewal and the stabilization of the structural integrity of the epithelial tissue.

These two mechanisms are constructively complementary. The enzymatic component mediates the reduction of the microbial load and the attenuation of local inflammatory signaling. This physiological condition permits the Pyridoxine component to facilitate the metabolic pathways required for the structural restoration of the mucosal barrier.

Administration Guidelines for Лисобакт Lozenge

The use of Лисобакт, a combination lozenge of Lysozyme Chloride and Pyridoxine Hydrochloride, is governed by a defined set of instructions. This section describes the administration protocols, adherence to which establishes the standardized approach to its use.

---

Administration Scope

Property	Instruction
Route of administration	Oral (intended for local, oropharyngeal application).
Dosing schedule	The standard regimen is 6 to 8 lozenges per day, with each lozenge typically containing 20 mg Lysozyme Chloride and 10 mg Pyridoxine Hydrochloride.
Timing in relation to meals (if applicable)	The medicine's action is officially not affected by the consumption of food or drinks.
Age-group administration rules	Approved for use in Adults and Pediatric patients over 6 years of age.

---

Instruction Classifications (High-level)

Classification	Description
Administration method type	Local Oral (dissolved in the mouth/pharynx).
Frequency pattern	Multiple times per day (up to 8 times daily).
Use-context constraints	A mandatory minimum interval of at least 1 hour must separate each lozenge intake.

---

Resulting Procedural Structure

Official step sequence:

• The lozenge must be placed in the mouth and allowed to slowly dissolve beneath the tongue (or in the oral cavity) to optimize local contact.
• The patient must adhere to a minimum interval of at least 1 hour between each lozenge.
• The treatment duration is officially limited to a maximum course of 5 days.
• If a dose is missed, patients are instructed to avoid taking a double dose and to continue with the regular dosing schedule.

This procedural structure defines the prescribed framework for administering the lozenge: a short-term, local oral regimen that dictates the required dissolution method, the precise frequency and interval, and the maximum allowed duration of use.

Research Evidence / Overview of Studies for Лисобакт

1. Evidence for Acute Oropharyngeal Inflammation

Research has examined the lozenge's application in conditions involving periods of heightened symptoms such as acute pharyngitis and tonsillitis. Studies exploring this area include Randomized Controlled Trials (RCTs) and comparative clinical trials, which are research formats used to monitor outcomes under controlled conditions. These studies have primarily focused on adult patients, and the research was conducted during periods of increased symptom activity.

The main outcomes monitored were patient-reported measures of throat pain intensity and assessments of changes in difficulty swallowing using standardized clinical scales. Researchers also monitored outcomes linked to inflammatory or irritative states over the study periods.

2. Evidence for Mucosal Healing and Localized Conditions

The research base for localized conditions and in scenarios involving tissue resolution involves comparative clinical trials and observational studies. The lozenge was studied for use in conditions associated with acute or disruptive episodes, such as mouth lesions (aphthae, stomatitis) and in the observation of recovery after procedures like tonsillectomy.

Research examined clinical observation points related to epithelial integrity and wound resolution. Specifically, studies monitored clinical measurements of mucosal tissue change and assessed the visual appearance and evolution of local lesions. In postoperative settings, research also monitored the patient use of supplemental pain medication during the observation period.

3. Long-Term Evidence and Follow-up Durations

Most clinical research related to the lozenge was observed in short-term research exploring short-term symptom changes that align with the typical course of acute infections or localized injuries. The follow-up durations for trials examining acute symptoms were typically limited to between 3 and 7 days.

There is limited information from research concerning long-term outcomes. Studies have not focused on maintenance of oral health, durability of effect, or the impact on long-term symptom patterns in conditions characterized by fluctuating or episodic manifestations. Consequently, long-term effects are not fully established, and current findings reflect patterns observed only over defined, short time intervals.

4. Research Gaps and Areas of Uncertainty

A key limitation is that comparative evidence is lacking in some areas, particularly concerning modern head-to-head trials against all available local therapies. The research base includes a mix of study designs, ranging from RCTs to pilot studies. Subgroup findings are uncertain, as many trials were not designed to provide detailed results for specific populations or different severity levels. Research is ongoing in this area.

Common questions about Лисобакт (FAQ)

Q: Can I drink alcohol while taking this medication?

A: Official product information advises against consuming alcohol while taking this medicine. Drinking alcohol may increase certain side effects of the medicine, such as feelings of sleepiness, dizziness, or difficulty concentrating. This advisory is included in the official product information.

Q: Is it safe to take this with an opioid pain medication?

A: Regulatory warnings state that taking this medicine alongside opioids or other drugs that depress the central nervous system (CNS) can increase the risk of serious side effects. This combination may lead to extreme drowsiness, severe breathing problems (respiratory depression), coma, and death.

Q: What should I do if I miss a dose?

A: According to the official product information, the advice is to take the dose as soon as you recall. If it is nearly time for your next scheduled dose, the advice is to skip the missed dose completely and continue your regular dosing schedule. Taking two doses at once is not recommended.

Q: Does this medicine affect my ability to drive?

A: Official regulatory documents indicate that this medicine can cause side effects such as dizziness, sleepiness, and decreased concentration. These effects may impair the ability to safely drive vehicles or operate complex machinery. It is generally advised to wait until you are aware of how the medicine affects you before engaging in these activities.

Q: Is it safe for children to use this medicine?

A: Based on official US indications, this medicine is approved as an add-on therapy for treating partial-onset seizures in pediatric patients who are 1 month of age and older. The appropriate dosage is typically determined individually by a healthcare provider.

Q: How long can I take this medicine for?

A: For treating neuropathic pain, the medicine's effectiveness has been specifically studied in controlled clinical trials lasting up to 12 weeks. For continuation of therapy beyond 12 weeks, the official documents indicate that the risks and benefits are assessed by a physician.

Q: What happens if I stop taking this suddenly?

A: Regulatory documents explicitly warn against stopping this medicine abruptly. Official guidelines recommend that it be withdrawn gradually over a period of at least one week. Sudden discontinuation may increase the frequency of seizures in patients with seizure disorders or lead to symptoms such as insomnia, headache, anxiety, or nausea.

Q: Can I take this medicine if I have kidney problems?

A: Official safety information notes that if a patient has kidney problems (renal impairment), the dose must be reduced and determined based on the level of kidney function. The official information indicates that a healthcare professional may need to adjust the dose.

How to Store and Dispose of Лисобакт

Storage and disposal of Lysobact (Lysozyme/Pyridoxine) must adhere strictly to the conditions specified in official regulatory documentation to maintain product quality and effectiveness.

Official Storage Requirements

Condition Type	Requirement
Temperature Limit	Do not store above 25 C (77°F).
Freezing Restriction	The product must not be frozen.
Child Safety	Keep out of the reach and sight of children.
Shelf Life	Must not be used after the expiry date shown on the package.

Disposal

Lysobact has a labeled stability period of 24 months. The medicine must be discarded if the expiration date has passed. Unused or expired Lysobact products must be disposed of according to local pharmaceutical waste regulations, ensuring they are not introduced into wastewater or household trash.